Current status and future directions of immune checkpoint inhibitors in EGFR-mutated advanced non-small cell lung cancer

LI Xingyuan, YU Yongfeng, MU Shuya, LU Shun

PDF(951 KB)
Tumor website：www.tumorsci.org E-mail Alert
PDF(951 KB)
Tumor ›› 2024, Vol. 44 ›› Issue (06) : 555-565. DOI: 10.3781/j.issn.1000-7431.2024.2401-0049
Expert Views

Current status and future directions of immune checkpoint inhibitors in EGFR-mutated advanced non-small cell lung cancer

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2024, 44(06): 555-565 https://doi.org/10.3781/j.issn.1000-7431.2024.2401-0049

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(951 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Tumor, All Rights Reserved.
E-mail: tumor@tumorsci.org
Powered by Beijing Magtech Co., Ltd.

/

〈 〉